U.S. Luxury Stock News

Comstock Resources, Inc.'s ( NYSE:CRK ) price-to-sales (or "P/S") ratio of 3.5x may not look like an appealing...

As the U.S. stock market reaches new highs, with major indices like the Dow and S&P 500 closing at record levels, small-cap stocks are capturing attention for their potential to outperform in this dynamic environment. With economic indicators showing a mix of strengths and challenges, identifying promising small-cap opportunities involves looking at factors such as earnings resilience and strategic insider actions that align with broader market trends.

As the Dow and S&P 500 close at record highs, reflecting a strong start to 2026, investors are keenly observing the broader market dynamics shaped by recent economic indicators and policy developments. In this environment of heightened market performance, identifying undervalued stocks becomes crucial for those looking to capitalize on potential growth opportunities amidst these record-setting indices.

The U.S. stock market has started 2026 with a bang, as major indexes like the Dow Jones Industrial Average and S&P 500 have hit record highs following a week of strong gains. This robust performance sets an intriguing backdrop for exploring investment opportunities in penny stocks, which often represent smaller or newer companies that can offer significant growth potential. Despite their somewhat outdated name, penny stocks remain relevant for investors seeking affordability combined with the...

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...

Unicycive Therapeutics, Inc. ( NASDAQ:UNCY ) is possibly approaching a major achievement in its business, so we would...

Key Insights Significantly high institutional ownership implies BioAge Labs' stock price is sensitive to their trading...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...

TriMas Corporation's ( NASDAQ:TRS ) price-to-earnings (or "P/E") ratio of 32.3x might make it look like a strong sell...

The Silicon Motion Technology Corporation ( NASDAQ:SIMO ) share price has done very well over the last month, posting...

While it may not be enough for some shareholders, we think it is good to see the Tucows Inc. ( NASDAQ:TCX ) share price...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Many The Andersons, Inc. ( NASDAQ:ANDE ) insiders ditched their stock over the past year, which may be of interest to...

Some Dycom Industries, Inc. ( NYSE:DY ) shareholders may be a little concerned to see that the Independent Director...

Key Insights Given the large stake in the stock by institutions, Oil-Dri Corporation of America's stock price might be...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Insiders who bought US$361.4k worth of Caleres, Inc. ( NYSE:CAL ) stock in the last year have seen some of their losses...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...

Key Insights Given the large stake in the stock by institutions, Heron Therapeutics' stock price might be vulnerable to...

Valens Semiconductor (VLN) is back on investor radar after securing a fourth MIPI A PHY design win in China and launching a production ready A PHY enabled e mirror with Sakae Riken Kogyo. See our latest analysis for Valens Semiconductor. The recent A PHY design wins and e mirror launch sit against a sharp short term rebound, with a 30 day share price return of 55.97% and year to date share price return of 58.97%. This contrasts with a 1 year total shareholder return decline of 19.48% and a 3...

LENZ Therapeutics and Lunatus Marketing & Consulting FZCO recently announced an exclusive agreement for Lunatus to register and commercialize VIZZ, an FDA-approved aceclidine-based eye drop for presbyopia, across multiple Middle East markets including the UAE, Saudi Arabia and Qatar. The deal builds on VIZZ’s early U.S. launch, where the product generated about US$1.6 million in Q4 2025 revenue from over 20,000 prescriptions and broad uptake by eye care professionals. We’ll explore how early...

Aquestive Therapeutics recently disclosed that the FDA has identified unspecified deficiencies in the New Drug Application for its orally delivered epinephrine film Anaphylm, pausing labeling discussions and potentially affecting the timing of any approval decision ahead of the scheduled 31 January 2026 PDUFA date. At the same time, the company is pressing ahead with plans to seek approvals for Anaphylm in Canada, Europe, and the UK in 2026, signaling an effort to build a global,...